CR20230015A - Fusiones heterodiméricas de relaxina y usos de las mismas - Google Patents

Fusiones heterodiméricas de relaxina y usos de las mismas

Info

Publication number
CR20230015A
CR20230015A CR20230015A CR20230015A CR20230015A CR 20230015 A CR20230015 A CR 20230015A CR 20230015 A CR20230015 A CR 20230015A CR 20230015 A CR20230015 A CR 20230015A CR 20230015 A CR20230015 A CR 20230015A
Authority
CR
Costa Rica
Prior art keywords
relaxin
heterodimeric
treatment
fusions
fusion polypeptides
Prior art date
Application number
CR20230015A
Other languages
English (en)
Spanish (es)
Inventor
Isabelle Sermadiras
Monika Anna Papworth
Judy Christiane Paterson
Peng Ke
Esther Marie Martin
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CR20230015A publication Critical patent/CR20230015A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CR20230015A 2020-06-17 2021-06-16 Fusiones heterodiméricas de relaxina y usos de las mismas CR20230015A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040250P 2020-06-17 2020-06-17
PCT/EP2021/066309 WO2021255127A1 (en) 2020-06-17 2021-06-16 Heterodimeric relaxin fusions and uses thereof

Publications (1)

Publication Number Publication Date
CR20230015A true CR20230015A (es) 2023-02-17

Family

ID=76584509

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230015A CR20230015A (es) 2020-06-17 2021-06-16 Fusiones heterodiméricas de relaxina y usos de las mismas

Country Status (17)

Country Link
US (3) US11795205B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168434A1 (cg-RX-API-DMAC7.html)
JP (2) JP7797423B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024994A (cg-RX-API-DMAC7.html)
CN (1) CN115916813B (cg-RX-API-DMAC7.html)
AR (1) AR125007A1 (cg-RX-API-DMAC7.html)
AU (3) AU2021290997C1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025019A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186143A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003578A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000038A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230015A (cg-RX-API-DMAC7.html)
EC (1) ECSP23002960A (cg-RX-API-DMAC7.html)
IL (1) IL298786A (cg-RX-API-DMAC7.html)
MX (1) MX2022016340A (cg-RX-API-DMAC7.html)
TW (1) TWI899263B (cg-RX-API-DMAC7.html)
WO (1) WO2021255127A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
JP2025517100A (ja) 2022-05-07 2025-06-03 北京拓界生物医薬科技有限公司 リラキシン又は類似体の融合タンパク質及びその医薬的使用
WO2024015634A2 (en) * 2022-07-15 2024-01-18 Nutcracker Therapeutics, Inc. Mrna therapies including sirp-alpha
IL321288A (en) 2022-12-09 2025-08-01 Astrazeneca Ab Dosing regimens using fusions of relaxin heterodimers
WO2024184206A1 (en) 2023-03-03 2024-09-12 Astrazeneca Ab Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8389475B2 (en) * 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
US9574010B2 (en) * 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AR094147A1 (es) * 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
DK3107938T3 (da) * 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
US11161891B2 (en) * 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2026053559A (ja) 2026-03-25
EP4168434A1 (en) 2023-04-26
CN115916813A (zh) 2023-04-04
US20220017591A1 (en) 2022-01-20
JP2023530335A (ja) 2023-07-14
KR20230024994A (ko) 2023-02-21
CN115916813B (zh) 2026-03-24
CA3186143A1 (en) 2021-12-23
AU2024200074B2 (en) 2025-11-27
AU2025252658A1 (en) 2025-11-13
JP7797423B2 (ja) 2026-01-13
IL298786A (en) 2023-02-01
US20240025958A1 (en) 2024-01-25
AU2021290997A1 (en) 2023-02-09
US12187774B2 (en) 2025-01-07
AR125007A1 (es) 2023-05-31
MX2022016340A (es) 2023-01-24
CL2022003578A1 (es) 2023-06-09
US11795205B2 (en) 2023-10-24
ECSP23002960A (es) 2023-03-31
US20250230214A1 (en) 2025-07-17
AU2021290997C1 (en) 2024-01-04
TWI899263B (zh) 2025-10-01
CO2023000038A2 (es) 2023-01-16
BR112022025019A2 (pt) 2022-12-27
AU2024200074A1 (en) 2024-01-25
AU2021290997B2 (en) 2023-10-12
TW202214673A (zh) 2022-04-16
WO2021255127A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
MX2022016340A (es) Fusiones heterodimericas de relaxina y usos de las mismas.
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
PH12020551907A1 (en) Antagonizing cd73 antibody
PE20250757A1 (es) Muteinas de interleucina 21 y metodos de tratamiento
ZA202304098B (en) Il-2 mutants and application thereof
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (es) Proteinas de fusion de albumina.
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
NO20080045L (no) Glykosylert UL-7, fremstilling og anvendelse av samme
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
WO2005077042A3 (en) Albumin fusion proteins
WO2022256499A3 (en) Bcma targeting trispecific proteins and methods of use
CN116528889A8 (zh) 用于治疗胶质母细胞瘤的方法和组合物
GEAP202516650A (en) Stabilized pre-fusion hmpv fusion proteins
ZA202310639B (en) Interleukin 15 variants
Kim et al. Construction of chimeric human epidermal growth factor containing short collagen-binding domain moieties for use as a wound tissue healing agent
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.
PH12022553408A1 (en) Cytokine conjugates
WO2016048999A3 (en) Fgf21 truncations and mutants and uses thereof
CN107001416B (zh) 芋螺毒素肽κ-CPTx-btl04、其制备方法及应用
CN107001421B (zh) 芋螺毒素肽κ-CPTx-btl02、其制备方法及应用
EP3252071B1 (en) Conotoxin peptide kappa-cptx-btl03, preparation method therefor, and uses thereof
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.